• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

byNeel MistryandTeddy Guo
June 21, 2022
in Chronic Disease, Gastroenterology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab.

2. Patient-reported outcomes of stool frequency and abdominal pain scores were lower in the ustekinumab group compared to adalimumab (p=0.019).

Evidence Rating Level: 1 (Excellent)

Study Rundown: First-line treatment for Crohn’s disease includes steroids, immunomodulators, and biologics. TNF inhibitors and interleukin (IL)-12 and IL-23 inhibitors represent more potent biologic options that work at the molecular level. Ustekinumab, an IL-12 and IL-23 agent, and adalimumab, anti-TNF antibody, have both shown superiority over placebo in previous trials. However, whether one biologic is more effective than the other is not well known. This randomized controlled trial aimed to compare the safety and efficacy of two relatively novel monoclonal antibodies, ustekinumab and adalimumab, in patients with moderate-to-severe active Crohn’s disease. The primary outcome was the proportion of patients in clinical remission, defined by Crohn’s Disease Activity Index (CDAI) score <150, a year after randomization. According to study results, clinical remission at 52 weeks was not significantly different between the ustekinumab and adalimumab groups. Serious and overall adverse events were also similar between groups. A major limitation of this study was that data was only reported for up to one year from baseline. Given that Crohn’s is a chronic disease, a longitudinal assessment may be warranted.

Click to read the study in The Lancet

Relevant Reading: Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

In-depth [randomized-controlled trial]: From Jun 28, 2018, and Dec 12, 2019, 633 patients were assessed for eligibility across 121 hospitals in 18 countries. Included were patients ≥18 years of age with CDAI score between 220-450 with no response or contraindication to conventional therapy. Altogether, 386 patients (191 in ustekinumab and 195 in adalimumab) were included in the intention-to-treat analysis. The primary outcome of clinical remission was not statistically significant between treatment groups at week 52 (65% in ustekinumab vs. 61% in adalimumab, 95% confidence interval [CI] -6 to 14, p=0.42). The same was true for safety with 2% (4 of 191) patients in ustekinumab group reporting serious infections compared to 3% (5 of 195) in adalimumab group. Overall, findings from this study suggest that while both ustekinumab and adalimumab are both effective for treatment of moderate to severe active Crohn’s disease, no clinical difference in safety and efficacy was seen between the two after 52 weeks.

RELATED REPORTS

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

Upadacitinib significantly improves clinical remission rate for moderately to severely active ulcerative colitis

Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adalimumabbiologic naivebiologicsColitisCrohn's Diseasegastroenteritisinflammatory bowel diseaseinflammatory bowel disease (IBD)Ulcerative Colitisustekinumab
Previous Post

Unsweetened coffee consumption is associated with reduced risk of mortality

Next Post

Accelerated approval drugs incur significant fee-for-service Medicare costs

RelatedReports

Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Chronic Disease

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

June 30, 2022
Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Upadacitinib significantly improves clinical remission rate for moderately to severely active ulcerative colitis

June 14, 2022
Thalidomide may be effective in refractory pediatric Crohn’s disease
Chronic Disease

Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease

June 8, 2022
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Risankizumab induction therapy is effective for moderate-to-severe Crohn’s disease

June 7, 2022
Next Post
Estrogen withdrawal associated with perimenopausal depression

Accelerated approval drugs incur significant fee-for-service Medicare costs

Children’s hospital visits for suicide ideation and attempts are increasing

Islamic-based interventions may improve both depression and anxiety

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

SALT-ED: Normal Saline versus Balanced Crystalloids in Noncriticaly Ill Adults [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Hybrid immunity protects against infection with omicron variant of COVID-19
  • #VisualAbstract: Tirzepatide Once Weekly for the Treatment of Obesity
  • Wellness Check: Sleep
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.